Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment of Helicobacter pylori infection: a prospective, multicenter, randomized controlled trial.
Ann MedAug 9, 2026 (epub)
Zhaoli Ma, Xi Gou, Hongjuan Ma et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized controlled trial compared 14-day keverprazan-amoxicillin therapy (KA) with esomeprazole-amoxicillin therapy (EA) in 264 treatment-naive adults with Helicobacter pylori infection. The study found that the eradication rates were 87.9% for KA and 80.3% for EA in the intention-to-treat analysis, indicating non-inferiority of KA therapy.
Key findings
- In the intention-to-treat analysis, eradication rates were 87.9% for KA and 80.3% for EA (p = 0.092).
- In the modified intention-to-treat analysis, eradication rates were 92.1% for KA and 86.2% for EA (p = 0.135).
- In the per-protocol analysis, eradication rates were 93.5% for KA and 88.3% for EA (p = 0.155).
- Adverse events and patient adherence were similar between the KA and EA groups.
Why it matters
The findings suggest that keverprazan-based therapy is a viable first-line treatment option for Helicobacter pylori infection, offering comparable efficacy and tolerability to the standard esomeprazole-based therapy.